摘要
目的探讨环磷酰胺联合泼尼松在治疗系统性红斑狼疮中的疗效及安全性。方法选取2011年8月至2014年8月我院收治的系统性红斑狼疮患者82例,在患者自愿的前提下随机分成两组,对照组给予泼尼松治疗,观察组给予环磷酰胺联合泼尼松治疗,检测两组患者治疗前后血清中免疫球蛋白及补体C3、C4水平变化情况,并对比两组患者的疗效及治疗期间不良反应的发生情况。结果治疗后1个月及3个月观察组各免疫球蛋白水平显著低于对照组,而血清补体水平显著高于对照组,差异有统计学意义(P<0.05);治疗后3个月,观察组的治疗总有效率显著高于对照组的治疗总有效率,差异有统计学意义(P<0.05);而治疗期间,两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论环磷酰胺联合泼尼松治疗系统性红斑狼疮疗效显著,安全可靠,值得在临床上推广使用。
Objective To investigate the efficacy and safety of combination of cyclophosphamide and prednisone in the treatment of systemic lupus erythematosus. Methods A total of 82 cases of systemic lupus erythematosus in our hospital from August 2011 to 2014 August. Patients were randomly divided into two groups,control group was given prednisone treatment,the observation group treated with cyclophosphamide and prednisone. Serum immunoglobulin protein and complement C3,C4 were observed before and after the treatment. The results were compared between two groups,curative effect and adverse reactions were also evaluated. Results One months and threemonths after treatment,the levels of serum immunoglobulin were significantly lower than those in control group,and serum P level was significantly higher than that in control group. The total effective rate was significantly higher than that in control group. The differences were statistically significant（ P〈0. 05）.Conclusion Cyclophosphamide combined with prednisone in the treatment of systemic lupus erythematosus showed safe and reliable. It is recommended to be used clinically.
出处
《标记免疫分析与临床》
CAS
2016年第4期400-402,共3页
Labeled Immunoassays and Clinical Medicine
